Floatz logo

ABATACEPT RECOMBINANT

Fanconi Anemia

Emory Universityprotein_peptidePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

16 Active assets in the Fanconi Anemia cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Porteus, Matthew, MD
Phase 2/3BBB
Fludarabine
Porteus, Matthew, MD
Phase 2/3BBB
FILGRASTIM
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2BBB
CYCLOSPORIN A
Fred Hutchinson Cancer Center
Phase 2BBB
Busulphan
Masonic Cancer Center, University of Minnesota
Phase 2/3BBB

View all 43 →

Same molecule, other indications

ABATACEPT RECOMBINANT is also rated in:

Primary Biliary CholangitisDormant
BB
Indicative ·
69 / 100
View asset →
acute lymphoblastic leukemiaDormant
BB
Indicative ·
68 / 100
View asset →
primary biliary cholangitisDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →